Nation
World
Politics
Sports
Business
Entertainment
Life
Tech
Science
Opinion
Crime
Health
Oddities

Alnylam’s experimental Alzheimer’s drug shows benefits in patients for six months

Por: The Boston Globe Business July 17, 2023

thumbnail

Alzheimer’s patients who received a single dose of an experimental gene-silencing treatment from Alnylam Pharmaceuticals showed benefits for six months in a small study, the Cambridge biotech said Monday.Alnylam reported in April that recipients of the medicine experienced reductions as high as 84 and 90 percent in two protein biomarkers that researchers say foreshadow the formation of amyloid, a sticky protein that builds up in plaques in the... + full article



Similar News

Alnylam deploys gene-silencing in early study aimed at subduing Alzheimer’s

The Boston Globe USA Business April 26, 2023

thumbnailCambridge scientists are deploying a novel gene-silencing technology used against ultra-rare diseases in a new effort to subdue Alzheimer’s, the memory-raving disorder that afflicts tens of millions of people worldwide.In findings reported Wednesday afternoon, Alnylam... + más

Alnylam halts work on eye drug, citing new US law over pricing | The Boston Globe

Reimagining Alzheimer’s (Part 8): APOE4 Removal Reduces Symptoms Of Alzheimer’s Disease | Forbes


High school scores and top performers from Friday, March 24

Orlando Sentinel USA Sports March 25, 2023

thumbnailOrangewood Christian 11, The Master’s Academy 1 Buzz: Austin Waring threw 5 innings of 1-run ball (0 earned runs) while allowing 4 hits and striking out 8 for Orangewood Christian. He lowered his season ERA to 0.78. Aiden McKee went 3-for-3 with a double, a walk, an RBI and a... + más

NFL Playoff Scenarios | ABC News

Le Krewe du Roi celebrates the state at 58th annual Mardi Gras Ball | The Advocate


Here's what disease does to brain, signs to look for: Alzheimer's Q&A

The Advocate USA Health January 02, 2023

thumbnailWhat is Alzheimer’s disease?German neurologist Dr. Alois Alzheimer first identified this neurological disorder in 1906 while studying the pathology of a woman he had treated for an unusual mental illness.While examining her brain after her death, Alzheimer noticed marked... + más

How To Spot The Early Signs Of Alzheimer's | Newsweek

Reimagining Alzheimer’s (Part 4): Cautious Optimism For A New Alzheimer’s Disease Treatment | Forbes


What You Should Know About The Anti-Alzheimer’s Drug Lecanemab

Forbes USA Business December 09, 2022

thumbnailan elderly woman exercising to combat Alzheimer's disease in a care center for elderly, Galicia, ... [+] 27th November 2007. (Photo by Xurxo Lobato/Cover/Getty Images)Cover/Getty Images What should people living with dementia and their families take away from the the... + más

Reimagining Alzheimer’s (Part 4): Cautious Optimism For A New Alzheimer’s Disease Treatment | Forbes

5 things to know about the new Alzheimer’s drug — including why it may be risky for people who take blood thinners | MarketWatch


ALNY Reiterates Guidance, TVTX Loss Widens, DXCM Paints Rosy Outlook

RTTNews USA Health October 28, 2022

thumbnailThe following are some of the companies belonging to the healthcare sector that reported quarterly financial results on Thursday.Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), which reported lower-than-expected financial results for the third quarter, has reiterated FY 2022 net... + más

Help Wanted: Treasury And The IRS Gear Up On Energy Tax Guidance | Forbes

Health Care — Trump staffers interfered in CDC guidance, report finds | The Hill


Alnylam halts work on eye drug, citing new US law over pricing

The Boston Globe USA Business October 27, 2022

thumbnailAlnylam Pharmaceuticals Inc. said it’s stopping work on a treatment for a rare eye disease because of a new US drug-pricing law with the potential to limit how much it could charge for the medication in the future.Alnylam will not begin a planned late-stage trial of its drug... + más

ALNY Reiterates Guidance, TVTX Loss Widens, DXCM Paints Rosy Outlook | RTTNews

Halted Stocks | Forbes


Reimagining Alzheimer’s (Part 4): Cautious Optimism For A New Alzheimer’s Disease Treatment

Forbes USA Tech October 22, 2022

thumbnailA person walks on a suspended rope bridge in the clouds. Extreme attraction.getty This article is the fourth installment in my series on Alzheimer’s disease. Read more about Alzheimer’s disease in , , and of the series. The pharmaceutical and biotech companies, Eisai and... + más

COVID-19 in seniors linked to increased Alzheimer’s risk, study finds | Portland Press Herald

Variety of factors play a role in the development of Alzheimer's | The Advocate



About iurex | Privacy Policy | Disclaimer |